ArticleAnnals of hematology2020

Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas.

Ella Willenbacher et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.